<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary pulmonary coccidioidal infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary pulmonary coccidioidal infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary pulmonary coccidioidal infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janis E Blair, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil M Ampel, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Coccidioidomycosis is the infection caused by the dimorphic fungi of the genus <em>Coccidioides</em>. Primary pulmonary infection is caused by inhalation of airborne mycelial arthroconidia located in soil. While most infections are asymptomatic, clinical illness ranges from acute pneumonia (Valley Fever) to extrathoracic disseminated infection  (<a class="graphic graphic_table graphicRef121586" href="/d/graphic/121586.html" rel="external">table 1</a>). Most cases of coccidioidomycosis in the United States are acquired in the southwestern part of the country, particularly in Arizona and the San Joaquin Valley of California.</p><p>The clinical manifestations, diagnostic approach, and management of primary pulmonary infection will be reviewed here. Extrathoracic coccidioidomycosis and complications and prevention of infection are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2444.html" rel="external">"Management of pulmonary sequelae and complications of coccidioidomycosis"</a> and  <a class="medical medical_review" href="/d/html/2445.html" rel="external">"Coccidioidal meningitis"</a> and  <a class="medical medical_review" href="/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"</a> and  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients"</a>.)</p><p class="headingAnchor" id="H1073167939"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Coccidioidomycosis is caused by the dimorphic fungi of the genus <em>Coccidioides </em>[<a href="#rid1">1</a>]. It is now recognized as consisting of two species, <em>Coccidioides immitis</em> and <em>Coccidioides posadasii</em> [<a href="#rid2">2,3</a>]. However, there is no clinical distinction between these two species, and henceforth the organism will be referred to as <em>Coccidioides</em>.</p><p><em>Coccidioides</em> grows as a mold no more than a few inches below the surface of the soil. Its precise ecologic niche is unclear. The mycelia consist of chains of cells that are approximately 3 to 5 microns in size. Alternating cells degenerate, releasing single cells, called arthroconidia; these cells can remain suspended for prolonged periods of time in the air and penetrate deep into the host airway. (See <a class="local">'Pathogenesis'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1198359612"><span class="h2">Geographic distribution</span><span class="headingEndMark"> — </span>While it has been estimated that there are approximately 150,000 coccidioidal infections each year in the United States [<a href="#rid4">4</a>], more recent calculations suggest that the number is far higher than this [<a href="#rid5">5</a>]. Coccidioidomycosis is endemic to certain regions of the Western Hemisphere; these include specific areas of the United States as well as northern Mexico and areas of Central and South America. </p><p>In the United States, most cases of coccidioidomycosis are reported from the San Joaquin Valley of California or from the south-central region of Arizona, including Maricopa and Pima counties, which contain the metropolitan areas of Phoenix and Tucson [<a href="#rid6">6,7</a>]. However, other regions of California, including areas of San Luis Obispo, Ventura, Los Angeles, Riverside, and San Diego counties, have regularly reported cases. In addition, southern Nevada, southwestern Utah, and southern New Mexico have endemic regions. Although not a reportable disease in Texas, the Permian Basin region, including the cities of Midland and Odessa, and the Rio Grande Valley, appear to be endemic for coccidioidomycosis. </p><p>Distinct pockets of coccidioidomycosis outside the generally recognized endemic regions have been identified by focal outbreaks of cases. These include an area in eastern Washington state [<a href="#rid8">8-10</a>], a Native American site in Dinosaur National Monument in northeast Utah [<a href="#rid11">11</a>], and an area in the Sierra foothills east of Red Bluff in northern California [<a href="#rid12">12</a>].</p><p>There has been a substantial increase in the incidence of coccidioidomycosis in the United States. For example, the incidence of coccidioidomycosis has increased from 5.2 cases per 100,000 in 1990 to 160.6 cases per 100,000 in 2020 in Arizona [<a href="#rid13">13</a>] and from 4.3 cases per 100,000 in 2001 to 18.1 cases per 100,000 in 2020 in California [<a href="#rid14">14</a>]. Several factors that may account for much of this increase have been identified in Arizona. These include a shift to more sensitive serologic test results to define cases, climate change causing prolonged drought, and continued migration of older and presumably uninfected persons into the endemic areas [<a href="#rid7">7,15</a>].</p><p>A number of notable outbreaks of coccidioidomycosis have occurred. In California, inmates of two state prisons in the highly endemic San Joaquin Valley were disproportionately affected by coccidioidomycosis compared with the general population, with 180 cases recognized in 2005 [<a href="#rid16">16</a>]. In another instance, a cluster of seven cases occurred among a highway construction crew in Kern County, California [<a href="#rid17">17</a>]. Between 2016 and 2017, there was an outbreak of coccidioidomycosis among workers constructing a solar power farm in Monterey County, California where the worksite-specific incidence rate was substantially higher than background county rates [<a href="#rid18">18</a>], and there was an outbreak among firefighters battling California wildfires [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Risk of infection</span><span class="headingEndMark"> — </span>The risk of infection by <em>Coccidioides</em> spp within known endemic areas is approximately 3 percent per year [<a href="#rid20">20</a>]. Thus, even those who have lived in endemic regions for many years may still be susceptible to new infection. In a telephone survey of patients diagnosed with Valley Fever conducted by the Arizona Department of Health Services, the average time of residence was 16 years [<a href="#rid21">21</a>]. </p><p>The risk of exposure within endemic regions is seasonal, typically being highest in dry periods following a rainy season. Periods of high incidence in Arizona range from May into July and then between October and early December [<a href="#rid22">22</a>]. By contrast, the Central Valley in California, which rarely receives significant summer rain, has a single peak from late spring to late fall. </p><p>Patients with impaired cellular immunity are at higher risk of severe and/or disseminated infection. As an example, in patients with rheumatologic diseases, the increased use of immunosuppressive regimens (eg, tumor necrosis factor alpha inhibitors) increased the risk of more extensive coccidioidal infection [<a href="#rid23">23</a>].</p><p>Previously acquired quiescent and clinically inapparent coccidioidal infection can reactivate in the setting of immunosuppression. This is because immunologic control of coccidioidomycosis occurs without eradicating <em>Coccidioides </em>spp from the body. Stable, asymptomatic, solitary pulmonary nodules may yield viable <em>Coccidioides</em> spp many years after infection [<a href="#rid24">24</a>]. In one report, a patient with HIV developed active coccidioidal disease in Spain approximately 12 years after leaving the endemic Southwestern United States [<a href="#rid25">25</a>]. The risk of reactivation appears to depend upon the level of immunosuppression. The extent of underlying Hodgkin lymphoma has been correlated with severity of coccidioidal infection and death [<a href="#rid26">26</a>], and in patients with HIV, loss of<em> </em>in vitro T-cell responsiveness to coccidioidal antigen exposure has been associated with more symptomatic coccidioidomycosis [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Infection is usually acquired by inhalation of arthroconidia. In most cases, no specific environmental exposure is identified and it is presumed that infection has occurred from inhalation of arthroconidia that are airborne. Evidence in the Phoenix metropolitan region indicates that airborne arthroconidia are common and may persist for prolonged periods of time [<a href="#rid28">28</a>]. Once within the lung, barrel-shaped arthroconidia change into spherical structures that then greatly enlarge, sometimes becoming as many as 200 microns in diameter. Enlarging spherules produce internal septations, and within each of the resulting subcompartments, individual cells called endospores develop.</p><p>After several days, mature spherules rupture, releasing endospores into the infected tissue; each endospore is potentially capable of producing another spherule [<a href="#rid1">1</a>]. <em>Coccidioides</em> spp exist in the spherule stage within the host, but revert to the mycelial form in the environment, including when plated onto artificial media in the laboratory [<a href="#rid29">29,30</a>]. These cultures represent a significant laboratory hazard [<a href="#rid31">31</a>].</p><p>The cellular immune response appears to be the controlling factor in coccidioidomycosis. Patients with resolving acute coccidioidal pneumonia express delayed-type hypersensitivity [<a href="#rid32">32</a>], and bronchoalveolar leukocytes from patients with pulmonary coccidioidomycosis release interferon gamma and other inflammatory cytokines in response to in vitro antigen stimulation [<a href="#rid33">33</a>]. Although there may be an initial polymorphonuclear cell response, once controlled, the pulmonary lesions are characterized by caseating granulomata with an active T-cell response [<a href="#rid34">34</a>]. In immunocompromised patients, the diminished cellular immune response results in less well-formed granulomas that contain a greater number of organisms than those seen in immunocompetent patients [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H273761226"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Patients who develop primary pulmonary infection can present with a range of pulmonary symptoms as well as extrapulmonary manifestations that are immunological in nature  (<a class="graphic graphic_table graphicRef121586" href="/d/graphic/121586.html" rel="external">table 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic/minimally symptomatic disease</strong> – At least 60 percent of all coccidioidal infections do not come to medical attention because primary infection is either asymptomatic or minimally symptomatic [<a href="#rid36">36,37</a>]. The proportion of infections that become clinically apparent increases in outbreaks with more intensive exposure to arthroconidia, such as might occur during archaeologic excavations or desert military maneuvers [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal pneumonia</strong> – Symptomatic infection due to<em> Coccidioides</em> spp most frequently presents in a manner similar to bacterial community-acquired pneumonia (CAP) in both immunocompetent and immunocompromised individuals [<a href="#rid40">40-42</a>]. Symptoms occur approximately 7 to 21 days after an exposure, which may or may not be apparent. The most common presenting symptoms are chest pain, cough, and fever  (<a class="graphic graphic_table graphicRef69260" href="/d/graphic/69260.html" rel="external">table 2</a>). In a study from Pima County, Arizona, 29 percent of patients diagnosed with CAP were serologically positive for coccidioidal infection at the time of presentation. A subsequent study from Phoenix, Arizona found a rate of 17 percent [<a href="#rid12">12,43-51</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse reticulonodular pneumonia</strong> – Diffuse reticulonodular pneumonia is a less common presentation that results from hematogenous seeding of the lungs [<a href="#rid52">52</a>]. This presentation is seen most commonly in immunosuppressed patients but can also occur in immunocompetent patients who are exposed to a high inoculum of arthroconidia [<a href="#rid40">40-42,52</a>]. Some patients with diffuse pulmonary disease may be clinically stable without respiratory compromise while others are markedly dyspneic at rest or with minimal exertion and develop symptoms such as fever and night sweats. Such patients frequently progress to respiratory failure requiring mechanical ventilation and often will develop fungemia [<a href="#rid48">48</a>]. Severe diffuse pulmonary disease can be associated with a high mortality [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic symptoms</strong> – Night sweats, headache, rash, weight loss, and fatigue are systemic symptoms that are associated with coccidioidomycosis. Any of these findings should alert the practitioner to the possibility of coccidioidomycosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunologic manifestations </strong>– Immunologic manifestations are frequent in primary pulmonary coccidioidomycosis and are usually expressed as cutaneous or rheumatologic symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous manifestations – The cutaneous manifestations of primary pulmonary coccidioidal infection include erythema nodosum (usually manifesting as painful, erythematous nodules on the lower extremities), as well as erythema multiforme, which is often seen in a necklace distribution. A toxic erythema consisting of a diffuse, sandpaper-like rash has also been observed. In one report, a patient with acute pulmonary coccidioidomycosis had a rash that was histopathologically consistent with Sweet syndrome [<a href="#rid53">53</a>]. Cutaneous manifestations are more common in females than in males. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rheumatologic symptoms – Patients less frequently present with symmetric arthralgias, particularly of the ankles, knees, and wrists. Their symmetricity and lack of local erythema and joint effusions distinguish these from disseminated disease and have been termed "desert rheumatism".</p><p></p><p class="bulletIndent1">These immunologic extrapulmonary manifestations associated with primary pulmonary infection do <strong>not</strong> represent disseminated disease  (<a class="graphic graphic_table graphicRef121586" href="/d/graphic/121586.html" rel="external">table 1</a>). Discussions of disseminated infection are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"</a> and  <a class="medical medical_review" href="/d/html/2445.html" rel="external">"Coccidioidal meningitis"</a>.)</p><p></p><p class="headingAnchor" id="H1117712947"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Routine laboratory findings are generally unremarkable [<a href="#rid54">54</a>]. The peripheral blood leukocyte count is usually normal or only slightly elevated; however, peripheral blood eosinophilia (&gt;5 percent) may be found in approximately one-quarter of patients [<a href="#rid1">1</a>]. The erythrocyte sedimentation rate is often one- or twofold above the upper limit of normal. Hypercalcemia is sometimes observed [<a href="#rid55">55</a>]. Serum procalcitonin levels are usually below 0.25 ng/mL [<a href="#rid56">56,57</a>], and levels of beta-(1,3)-D-glucan are variably elevated [<a href="#rid58">58,59</a>] and should not be relied upon for diagnosis. </p><p class="headingAnchor" id="H1228570242"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Although initial infections usually demonstrate a pulmonary infiltrate, occasionally standard posteroanterior and lateral chest radiographs may be unremarkable. </p><p>When present, a common radiographic abnormality is a unilateral dense infiltrate with ipsilateral hilar adenopathy  (<a class="graphic graphic_diagnosticimage graphicRef76967" href="/d/graphic/76967.html" rel="external">image 1</a>). Mediastinal adenopathy may also be present. Hilar and mediastinal adenopathy do not occur in bacterial pneumonia and should alert the practitioner to the possibility of coccidioidomycosis. In addition, the pulmonary infiltrate in coccidioidomycosis is often in the upper lobes, distinctly different from bacterial processes. Occasionally, ipsilateral parapneumonic effusions can occur [<a href="#rid60">60</a>]. Nodules or thin-walled pulmonary cavities are detected in 4 to 8 percent of all patients  (<a class="graphic graphic_diagnosticimage graphicRef51795" href="/d/graphic/51795.html" rel="external">image 2</a>) [<a href="#rid61">61</a>]. In some cases, empyema may occur due to rupture of a coccidioidal cavity into the pleural space [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/2444.html" rel="external">"Management of pulmonary sequelae and complications of coccidioidomycosis", section on 'Coccidioidal cavities'</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1017503989"><span class="h2">When to suspect infection</span><span class="headingEndMark"> — </span>We consider the diagnosis of coccidioidomycosis in patients living in or who have traveled to an endemic area who present with any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A respiratory illness of one week or more with an infiltrate on chest radiograph, especially if there is upper lobe involvement or hilar or mediastinal adenopathy. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presumed community-acquired pneumonia (CAP) with continued pulmonary symptoms despite appropriate empiric antibacterial therapy. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of rash, particularly if consistent with erythema nodosum or erythema multiforme, or the onset of diffuse, symmetrical arthralgias. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other findings suggestive of coccidioidomycosis, including night sweats, marked fatigue, weight loss, or unexplained peripheral blood eosinophilia. (See <a class="local">'Signs and symptoms'</a> above and <a class="local">'Laboratory findings'</a> above.)</p><p></p><p>Because exposure usually occurs within an endemic region, it is critical to obtain an accurate travel history [<a href="#rid11">11,63-66</a>], especially in those residing outside the typical endemic region. It is important to consider the diagnosis of primary pulmonary coccidioidal infection in persons who develop CAP within the one- to three-week incubation period after visiting an endemic area [<a href="#rid63">63,67</a>]. Even brief exposures in the endemic region have been sufficient to cause infection. As an example, eight cases of primary pulmonary coccidioidomycosis were reported in four states (Kansas, Maryland, Michigan, and New York) in persons who traveled to Baja California, Mexico to construct houses [<a href="#rid67">67</a>]. </p><p>Identifying coccidioidal infections as early as possible has many benefits, including: allaying patient anxiety by arriving at a specific diagnosis, often simultaneously dispelling the fear of cancer; reducing the need for additional diagnostic testing, which can involve invasive or costly procedures; eliminating empiric or protracted use of antibacterial treatments; and reducing the morbidity of less frequent but progressively destructive extrapulmonary complications, most of which develop within the first several months following the initial infection [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/d/html/2444.html" rel="external">"Management of pulmonary sequelae and complications of coccidioidomycosis"</a>.)</p><p>However, many coccidioidal infections are not identified because the symptoms, signs, and routine laboratory findings are nonspecific, and clinicians do not consider the diagnosis. Low rates of disease recognition have occurred in both nonendemic and endemic areas [<a href="#rid22">22,63,67,69,70</a>]. In a study that evaluated data from two medical centers in metropolitan Phoenix, Arizona, the number of patients with CAP tested for Valley Fever was only 2 and 13 percent, respectively [<a href="#rid70">70</a>]. </p><p class="headingAnchor" id="H1036088807"><span class="h2">Diagnostic testing</span><span class="headingEndMark"> — </span>In most patients, the diagnosis of primary coccidioidal infection relies upon serologic testing  (<a class="graphic graphic_table graphicRef121586" href="/d/graphic/121586.html" rel="external">table 1</a>). Serologic tests using enzyme-linked immunoassays (EIAs) for IgM and IgG should be ordered first, if possible [<a href="#rid71">71</a>]. Immunodiffusion tests are generally performed to support the diagnosis when an initial EIA is positive. (See  <a class="medical medical_review" href="/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening", section on 'Detection of anticoccidioidal antibodies'</a>.)</p><p>However, in some patients with early disease, antibody response may be delayed. In one report, serologic evidence of infection was negative in as many as one-third of patients [<a href="#rid41">41</a>]. In such patients, repeating the coccidioidal serologic tests weekly can be helpful.</p><p>For those with severe/extensive disease (eg, diffuse reticulonodular pneumonia), more aggressive diagnostic measures, such as a bronchoalveolar lavage, are often performed. In this setting, cytologic examination may reveal spherules. Although fungal cultures of bronchoalveolar lavage fluid are more sensitive than of sputum, it may take several days before growth is evident [<a href="#rid72">72</a>]. If coccidioidal polymerase chain reaction testing is available, this is as sensitive as culture but can be faster for establishing the diagnosis [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening", section on 'Recovery of Coccidioides from clinical specimens'</a>.)</p><p>When cultures to detect <em>Coccidioides</em> spp are obtained, the clinician caring for the patient should alert the microbiology laboratory that coccidioidomycosis is a likely possibility, because appropriate biocontainment procedures are needed [<a href="#rid31">31</a>]. Exposure to <em>Coccidioides</em> spp in the laboratory setting can lead to infection of laboratory staff. (See  <a class="medical medical_review" href="/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening", section on 'Recovery of Coccidioides from clinical specimens'</a>.)</p><p class="headingAnchor" id="H630889929"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H2910259033"><span class="h2">Determining disease severity and risk factors</span><span class="headingEndMark"> — </span>The approach to treatment of primary pulmonary coccidioidal infection depends upon the severity of disease and the patient's risk of developing severe or disseminated complicated disease. Although many patients with primary pulmonary coccidioidal infection do not require antifungal therapy, treatment should be administered to those with moderate and severe disease and those at high risk for developing more serious/complicated disease  (<a class="graphic graphic_table graphicRef121808" href="/d/graphic/121808.html" rel="external">table 3</a>). </p><p>Commonly used indicators for moderate disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>Infiltrates involving more than half of one lung or portions of both lungs, regardless of symptoms (see <a class="local">'Signs and symptoms'</a> above and <a class="local">'Imaging'</a> above) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent symptoms of infection, particularly cough, fever, and night sweats, for longer than three weeks (see <a class="local">'Signs and symptoms'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Greater than 10 percent loss of body weight (see <a class="local">'Signs and symptoms'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticoccidioidal complement-fixing antibody concentrations ≥1:32 (see <a class="local">'Diagnostic testing'</a> above)</p><p></p><p>Severe disease is defined by the presence of respiratory compromise. (See <a class="local">'Severe disease'</a> below.)</p><p>High risk factors for developing severe and/or complicated disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>Major suppression of cellular immunity, which can be seen in patients with HIV and CD4 cell count &lt;250 cells/microL [<a href="#rid41">41,42</a>], those undergoing solid organ or hematopoietic cell transplantation [<a href="#rid74">74-76</a>], and those receiving immune-suppressing agents, such as high-dose glucocorticoids (eg, 20 mg or more per day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or its equivalent) [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Immunocompromised patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic malignancies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer chemotherapy associated with cytopenia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy when disease develops during the second or third trimester or immediately postpartum. (See  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Pregnant patients'</a>.)</p><p></p><p>Other individuals who may be at increased risk of complications include: those of African or Filipino descent, because these populations are at increased risk of extrapulmonary complications [<a href="#rid49">49,78,79</a>]; those with diabetes, given their higher risk of pulmonary complications, including cavitation [<a href="#rid80">80</a>]; frail older adults [<a href="#rid81">81,82</a>]; and those on anticytokine therapy for rheumatologic, gastrointestinal, or dermatologic diseases [<a href="#rid83">83</a>]. For these patients, we make the decision to provide antifungal therapy on a case-by-case basis. </p><p class="headingAnchor" id="H526683204"><span class="h2">Approach to antifungal therapy</span></p><p class="headingAnchor" id="H963321332"><span class="h3">Immunocompetent nonpregnant patients</span><span class="headingEndMark"> — </span>The initial approach to treatment in immunocompetent nonpregnant patients depends upon the severity of disease and the presence of risk factors for developing complications  (<a class="graphic graphic_table graphicRef121808" href="/d/graphic/121808.html" rel="external">table 3</a>). Our approach is consistent with guideline recommendations from the Infectious Diseases Society of America [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H1328015123"><span class="h4">Mild disease</span><span class="headingEndMark"> — </span>In general, antifungal therapy is <strong>not</strong> needed for healthy patients without evidence of extensive coccidioidal infection or risk factors for developing more serious infection [<a href="#rid4">4</a>]. Those with risk factors for severe disease (eg, African or Filipino descent, diabetes, frailty, presence of immunocompromising conditions) should be considered for treatment with triazole therapy, similarly to those with moderate disease  (<a class="graphic graphic_table graphicRef121808" href="/d/graphic/121808.html" rel="external">table 3</a>). (See <a class="local">'Determining disease severity and risk factors'</a> above and <a class="local">'Moderate disease'</a> below.)</p><p>Observational data indicate that antifungal therapy offers little benefit to those with mild disease [<a href="#rid84">84,85</a>]. As an example, in an observational study that evaluated 36 immunocompetent patients with primary pulmonary coccidioidomycosis followed for 24 weeks, the median time from diagnosis to a 50 percent reduction of symptoms was no different between those treated with an antifungal agent and those who were not treated [<a href="#rid85">85</a>]. Similarly, in an earlier study of 105 patients with primary pulmonary coccidioidomycosis, in which 54 patients were treated and 51 were not, there was no difference between the groups with respect to overall rates of improvement [<a href="#rid84">84</a>]. In this report, none of the untreated patients were found to have complications over a median of 286 days of follow-up. In both of these studies, patients who received treatment had more severe illness, since treatment was initiated based upon severity of disease as assessed by the attending staff.</p><p>However, all patients with primary coccidioidal infection, regardless of whether they were treated, should be followed for at least one year to monitor for the development of complications. (See <a class="local">'Patient monitoring'</a> below.)</p><p class="headingAnchor" id="H1494601102"><span class="h4">Moderate disease</span><span class="headingEndMark"> — </span>Antifungal therapy is indicated for immunocompetent patients with moderate disease. For most patients, we suggest <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg daily) for initial therapy; <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> (200 mg twice daily) is a good alternative  (<a class="graphic graphic_table graphicRef121808" href="/d/graphic/121808.html" rel="external">table 3</a>) [<a href="#rid4">4</a>]. There is no consensus regarding the duration of therapy. We generally treat patients for approximately 12 weeks, although shorter courses (eg, six weeks) may be reasonable for certain immunocompetent patients, such as those who have rapid clinical improvement over days to weeks. </p><p>Although <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> and <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> appeared to have similar efficacy for the treatment of pulmonary disease in a randomized controlled trial of 70 patients (54 versus 57 percent) [<a href="#rid86">86</a>], we usually prefer fluconazole for initial treatment because it is well absorbed and does not require therapeutic drug monitoring, has fewer drug interactions, and has a lower risk of hypokalemia, hypertension, and congestive heart failure. However, fluconazole causes predictable skin and mucous membrane dryness and occasional alopecia [<a href="#rid87">87</a>]. In addition, in the randomized trial mentioned above, fluconazole was associated with a nonsignificant increase in the risk of relapse compared with itraconazole (28 versus 18 percent) [<a href="#rid86">86</a>].</p><p>Although <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a> was approved for the treatment of coccidioidomycosis by the US Food and Drug Administration (FDA), this agent is no longer recommended because it has more toxicity than either <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>. There is little information available about the value of other azoles, such as <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, or <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, for treating primary coccidioidal pneumonia. However, clinical experience indicates that these triazole antifungals are at least as effective as fluconazole and itraconazole and may be appropriate in situations of toxicity or lack of response [<a href="#rid88">88-90</a>].</p><p>Discussions of patient monitoring and the management of those with refractory disease are found below. (See <a class="local">'Patient monitoring'</a> below and <a class="local">'Refractory disease'</a> below.)</p><p class="headingAnchor" id="H1843279600"><span class="h4">Severe disease</span><span class="headingEndMark"> — </span>For those meeting the criteria of moderate disease who also have respiratory compromise, we suggest initiating intravenous amphotericin B in combination with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> 400 to 800 mg daily (<a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> 200 mg twice daily is a good alternative) (see <a class="local">'Moderate disease'</a> above). To reduce toxicity, we prefer a lipid formulation of amphotericin B at a dose of 3 to 5 mg/kg daily. If the deoxycholate formulation is used instead, we administer a dosage of 0.5 mg/kg daily. (See  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B"</a>.)</p><p>Once clinically stable, the patient can transition to oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> monotherapy. In patients with severe disease, triazole therapy is generally given for at least 12 to 24 weeks. </p><p class="headingAnchor" id="H3781811517"><span class="h3">Immunocompromised patients</span><span class="headingEndMark"> — </span>Immunocompromised patients are at risk for developing severe or disseminated disease, and therefore require treatment even if they present with mild symptoms. </p><p>Immunocompromised patients include: </p><p class="bulletIndent2"><span class="glyph">•</span>Patients with HIV and CD4 cell counts &lt;250 cells/microL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transplant recipients who are on immunosuppression.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients receiving tumor necrosis factor alpha inhibitors, high-dose glucocorticoids, and certain other immunomodulators.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with solid tumor malignancies who are receiving lymphodepleting chemotherapy [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with active hematologic malignancies, as well as those in remission; severe illness has been reported in such patients even after completion of chemotherapy and radiation therapy [<a href="#rid92">92</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chimeric antigen receptor (CAR)-T cell therapy recipients [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with specific gene mutations (gamma-interferon receptor [IFN-gammaR1], IL-12 receptor [IL-12Rbeta1] [<a href="#rid94">94</a>], STAT1 [<a href="#rid95">95</a>], and STAT3 [<a href="#rid96">96</a>]). </p><p></p><p>The general principles of management of coccidioidomycosis in the immunocompromised host  (<a class="graphic graphic_table graphicRef121808" href="/d/graphic/121808.html" rel="external">table 3</a>) are the same as those for the normal host, but there are a few major differences:</p><p class="bulletIndent1"><span class="glyph">●</span>All immunocompromised patients with clinically active coccidioidomycosis at any anatomic site should receive antifungal therapy because of their high risk for both severe disease and extrathoracic dissemination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antifungal therapy is generally prolonged and often lifelong in those who remain immunocompromised. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Minimizing immunosuppression and improving cellular immunity in an immunocompromised patient is a key part of coccidioidomycosis therapy. In patients with HIV, this means initiation of ART as soon as safely possible and monitoring the patient closely for adherence and complications. In patients on immunosuppressive drugs (eg, transplant recipients), this means reduction in dose or complete discontinuation of immunosuppressants, when possible. Patients with specific gene mutations generally require prolonged antifungal therapy and, if possible, immune modulation therapy to overcome the genetic defect. </p><p></p><p>All such cases should be managed in conjunction with an infectious diseases expert who is experienced in the treatment of coccidioidomycosis.</p><p>Antifungal selection in immunocompromised patients is the same as in immunocompetent patients (see <a class="local">'Immunocompetent nonpregnant patients'</a> above). Aspects of management specific to certain groups of immunocompromised patients are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Immunocompromised patients'</a>.)</p><p>Screening and prevention of coccidioidomycosis in immunocompromised patients are discussed separately. (See  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients"</a>.)</p><p class="headingAnchor" id="H657664029"><span class="h3">Pregnant patients</span><span class="headingEndMark"> — </span>Approach to antifungal therapy in pregnant patients is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Pregnant patients'</a>.)</p><p class="headingAnchor" id="H96096634"><span class="h2">Patient monitoring</span><span class="headingEndMark"> — </span>All patients should be monitored for complications and/or relapse at regular intervals, regardless of whether they receive antifungal therapy. In addition, monitoring can help assess for toxicity and guide duration of therapy. (See <a class="local">'Moderate disease'</a> above and <a class="local">'Severe disease'</a> above.)</p><p class="headingAnchor" id="H1440721909"><span class="h3">What to monitor</span><span class="headingEndMark"> — </span>Patients should be monitored for clinical, serologic, and radiographic improvement. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – Patients should be monitored for improvement in both respiratory and systemic signs and symptoms. Patients with primary pulmonary coccidioidal infection should be monitored approximately every 6 to 12 weeks for improvement. During the weeks to months following presentation, respiratory symptoms (eg, cough and pleurisy) and systemic signs (eg, weight loss, night sweats, and fever) typically diminish or resolve. Once such improvement has occurred, intervals between clinic visits may be extended to every six months. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serology</strong> – Serologic testing for complement-fixing-type anticoccidioidal antibodies should be repeated about every 12 weeks. (See  <a class="medical medical_review" href="/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening", section on 'Detection of anticoccidioidal antibodies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>With clinical improvement, complement-fixing antibody titers should decline and eventually become undetectable. However, the decline in complement-fixing antibody titer can be slow and unpredictable [<a href="#rid97">97</a>], and the complement-fixing antibody titer should not be the sole test used to determine when to discontinue antifungal therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated titers, such as those ≥1:32, suggest continued fungal growth. This could be associated with progressive disease and, in some cases, suggests that extrathoracic dissemination may be occurring [<a href="#rid98">98</a>]. In such instances, careful correlation with clinical examination and imaging is required. (See <a class="local">'Refractory disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – When radiographic abnormalities are initially noted, they should be rechecked within the first 12 weeks following diagnosis and then again, several months later to determine if there is a residual nodule or cavity. Determining whether pulmonary lesions evolve into residual nodules is also useful because it obviates the need to investigate the etiology of this radiographic finding in the future. (See  <a class="medical medical_review" href="/d/html/2444.html" rel="external">"Management of pulmonary sequelae and complications of coccidioidomycosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects of therapy</strong> – Patients receiving antifungal therapy should be monitored for toxicity. This includes monitoring aminotransaminases in all patients and reviewing concurrent medications to avoid severe drug interactions [<a href="#rid89">89</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving amphotericin B, renal function and electrolytes should be monitored daily. (See  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, patients should be monitored for the development of severe xerosis and alopecia. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug-specific adverse effects'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those receiving <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>, patients should undergo therapeutic drug monitoring and measurement of serum potassium. Serial assessment for the development of peripheral edema and hypertension are also important. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug-specific adverse effects'</a> and  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>.)</p><p></p><p class="headingAnchor" id="H365874617"><span class="h3">Duration of monitoring</span><span class="headingEndMark"> — </span>For patients not treated with antifungal drugs, follow-up is usually complete by one year. However, those who receive antifungal therapy should be followed annually for at least two years after the completion of treatment, because later recurrences have been noted occasionally in such patients [<a href="#rid4">4</a>]. In the observational study of 105 patients with primary pulmonary coccidioidomycosis described above, 38 treated patients were followed after discontinuation of therapy, and eight had relapse or progression of their coccidioidal infection [<a href="#rid84">84</a>], emphasizing the importance of close and prolonged follow-up for patients who were treated. </p><p>Immunocompromised patients are generally treated longer than immunocompetent patients due to slower resolution of illness and risk of relapse. In addition, some patients may require suppressive therapy. (See  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Secondary prevention'</a> and  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Duration of therapy'</a>.)</p><p class="headingAnchor" id="H4291754411"><span class="h2">Refractory disease</span><span class="headingEndMark"> — </span>If the patient has not experienced clinical improvement and/or the patient has additional symptoms or signs, and complement-fixing antibody titers remain elevated, we typically search for evidence of pulmonary complications and for disseminated disease. In the latter cases, clinicians should ask about a persistent headache, new joint effusions, or new skin lesions. The clinical manifestations of these complications are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2444.html" rel="external">"Management of pulmonary sequelae and complications of coccidioidomycosis"</a> and  <a class="medical medical_review" href="/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"</a>.)</p><p>If there is evidence of persistent disease, it is reasonable to switch from <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> to <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>. Although the randomized trial comparing these agents did not demonstrate that either agent was superior to the other, there was a trend towards greater efficacy with itraconazole in patients with persistent infection for more than three months [<a href="#rid86">86</a>]. Thus, in this setting, the potential improved efficacy may be worth the increased risk of drug interactions and the need to monitor drug levels. Such patients should be managed in conjunction with an infectious diseases expert experienced in the management of coccidioidomycosis. In some cases, using other mold-active triazole antifungals, such as <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a>, or <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">isavuconazole</a>, may be required either because of lack of response or toxicity to fluconazole and itraconazole.</p><p class="headingAnchor" id="H503559955"><span class="h1">SEQUELAE OF PRIMARY PULMONARY INFECTION</span></p><p class="headingAnchor" id="H21453818"><span class="h2">Prolonged fatigue</span><span class="headingEndMark"> — </span>Fatigue and lethargy associated with coccidioidal pneumonia may persist for months, far beyond the resolution of all other symptoms and laboratory abnormalities [<a href="#rid99">99</a>]. Antifungal therapy is not helpful for these symptoms. However, reassurance and education about the protracted nature of fatigue are very important. Some patients may benefit from physical therapy.</p><p class="headingAnchor" id="H961851434"><span class="h2">Pulmonary complications</span><span class="headingEndMark"> — </span>Some patients develop pulmonary consequences of coccidioidomycosis, such as residual pulmonary nodules, coccidioidal cavities, chronic and progressive fibrocavitary pneumonia, and diffuse reticulonodular pneumonia. The management of these conditions is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2444.html" rel="external">"Management of pulmonary sequelae and complications of coccidioidomycosis"</a>.)</p><p class="headingAnchor" id="H3091181726"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113064.html" rel="external">"Society guideline links: Coccidioidomycosis"</a>.)</p><p class="headingAnchor" id="H529417242"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87358.html" rel="external">"Patient education: Valley Fever (coccidioidomycosis) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H907830"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Coccidioidomycosis is caused by the dimorphic fungi of the genus <em>Coccidioides</em>. Infection is caused by inhalation of arthroconidia  (<a class="graphic graphic_table graphicRef121586" href="/d/graphic/121586.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Coccidioidomycosis is endemic to certain arid regions of the Western Hemisphere, including the San Joaquin Valley of California, south-central Arizona, as well as other parts of the United States. It is also found in parts of Mexico and Central and South America. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– It is estimated that fewer than one-half of all infections come to medical attention, because illness is often subclinical. However, when illness is clinically significant, primary infection frequently manifests as community-acquired pneumonia approximately 7 to 21 days after exposure. Patients can also develop systemic complaints (eg, night sweats, weight loss, fatigue), as well as rheumatologic or cutaneous manifestations that are immunologic in nature. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect infection </strong>– We consider the diagnosis of coccidioidomycosis in patients living in or who have traveled to an endemic area who present with any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A respiratory illness of more than one week's duration with an infiltrate on chest radiograph, especially if there is upper lobe involvement or hilar or mediastinal adenopathy. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Presumed community-acquired pneumonia with continued symptoms despite appropriate empiric antibacterial therapy. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New onset of diffuse symmetrical arthralgias and/or the rash of either erythema nodosum or erythema multiforme. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent night sweats, weight loss, and fatigue; respiratory symptoms may occasionally be minimal in such patients. (See <a class="local">'When to suspect infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic testing </strong>– Diagnosis usually relies upon serologic testing. However, in patients with early disease, especially those with severe infection, repeated serologic testing or isolation of <em>Coccidioides</em> spp in culture may be needed to establish the diagnosis. (See  <a class="medical medical_review" href="/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild disease</strong> – Healthy patients without evidence of extensive coccidioidal infection or risk factors for more serious infection usually do not need antifungal therapy. Those with risk factors for severe disease (eg, African or Filipino descent, diabetes, frailty, immunocompromising condition) should be considered for treatment with triazole therapy, similarly to those with moderate disease  (<a class="graphic graphic_table graphicRef121808" href="/d/graphic/121808.html" rel="external">table 3</a>). (See <a class="local">'Determining disease severity and risk factors'</a> above and <a class="local">'Approach to antifungal therapy'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate disease </strong>– For patients with moderate pulmonary illness, we suggest antifungal therapy with either <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a>  (<a class="graphic graphic_table graphicRef121808" href="/d/graphic/121808.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe disease</strong> – For patients with respiratory compromise due to coccidioidomycosis, we suggest initiating lipid-formulated amphotericin B plus <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (<a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> is a good alternative) and then transitioning to triazole monotherapy when the patient is clinically stable  (<a class="graphic graphic_table graphicRef121808" href="/d/graphic/121808.html" rel="external">table 3</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Determining disease severity and risk factors'</a> above and <a class="local">'Mild disease'</a> above and <a class="local">'Moderate disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – We generally treat patients without respiratory compromise for approximately 12 weeks, although shorter courses (eg, six weeks) may be reasonable for certain patients, such as those who have rapid clinical improvement over days to weeks. Patients with severe disease warrant 12 to 24 weeks of therapy. (See <a class="local">'Approach to antifungal therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient monitoring </strong>– It is important that patients with coccidioidal infection, regardless of treatment, be followed for a year or longer to monitor for the development of complications. Patients should be monitored for clinical, serologic, and radiographic improvement. (See <a class="local">'Patient monitoring'</a> above and <a class="local">'Sequelae of primary pulmonary infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sequalae of infection</strong> – Some patients may develop fatigue and lethargy associated with coccidioidal pneumonia without evidence of complications, and this may persist for many weeks or months. Antifungal therapy is not helpful in this setting. (See <a class="local">'Prolonged fatigue'</a> above.)</p><p></p><p class="headingAnchor" id="H875423340"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John Galgiani, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol 2007; 45:26.</a></li><li><a class="nounderline abstract_t">Fisher MC, Koenig GL, White TJ, Taylor JW. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 2002; 94:73.</a></li><li><a class="nounderline abstract_t">Umeyama T, Sano A, Kamei K, et al. Novel approach to designing primers for identification and distinction of the human pathogenic fungi Coccidioides immitis and Coccidioides posadasii by PCR amplification. J Clin Microbiol 2006; 44:1859.</a></li><li><a class="nounderline abstract_t">Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clin Infect Dis 2016; 63:e112.</a></li><li class="breakAll">Freedman M, Anderson S, Benedict K, et al. Preliminary Estimates of Annual Burden of Coccidioidomycosis in the United States, 2010–2014. 7th International Conference on Coccidioidomycosis. Stanford University 2017.</li><li class="breakAll">Centers for Disease Control and Prevention. Vally Fever (Coccidioidomycosis) statistics. https://www.cdc.gov/fungal/diseases/coccidioidomycosis/statistics.html (Accessed on January 04, 2017).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Increase in reported coccidioidomycosis--United States, 1998-2011. MMWR Morb Mortal Wkly Rep 2013; 62:217.</a></li><li><a class="nounderline abstract_t">Marsden-Haug N, Goldoft M, Ralston C, et al. Coccidioidomycosis acquired in Washington State. Clin Infect Dis 2013; 56:847.</a></li><li><a class="nounderline abstract_t">Marsden-Haug N, Hill H, Litvintseva AP, et al. Coccidioides immitis identified in soil outside of its known range - Washington, 2013. MMWR Morb Mortal Wkly Rep 2014; 63:450.</a></li><li><a class="nounderline abstract_t">Litvintseva AP, Marsden-Haug N, Hurst S, et al. Valley fever: finding new places for an old disease: Coccidioides immitis found in Washington State soil associated with recent human infection. Clin Infect Dis 2015; 60:e1.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Coccidioidomycosis in workers at an archeologic site--Dinosaur National Monument, Utah, June-July 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1005.</a></li><li><a class="nounderline abstract_t">Werner SB, Pappagianis D, Heindl I, Mickel A. An epidemic of coccidioidomycosis among archeology students in northern California. N Engl J Med 1972; 286:507.</a></li><li class="breakAll">Arizona Department of Health Services. Disease Data, Statistics &amp; Reports - Data &amp; Statistics Past Years. https://www.azdhs.gov/preparedness/epidemiology-disease-control/index.php#data-stats-past-years (Accessed on December 14, 2022).</li><li class="breakAll">California Department of Public Health. Valley fever. https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/ValleyFeverDataPublications.aspx (Accessed on December 14, 2022).</li><li><a class="nounderline abstract_t">Hector RF, Rutherford GW, Tsang CA, et al. The public health impact of coccidioidomycosis in Arizona and California. Int J Environ Res Public Health 2011; 8:1150.</a></li><li><a class="nounderline abstract_t">Pappagianis D, Coccidioidomycosis Serology Laboratory. Coccidioidomycosis in California state correctional institutions. Ann N Y Acad Sci 2007; 1111:103.</a></li><li><a class="nounderline abstract_t">Nicas M. A point-source outbreak of Coccidioidomycosis among a highway construction crew. J Occup Environ Hyg 2018; 15:57.</a></li><li><a class="nounderline abstract_t">Laws RL, Cooksey GS, Jain S, et al. Coccidioidomycosis Outbreak Among Workers Constructing a Solar Power Farm - Monterey County, California, 2016-2017. MMWR Morb Mortal Wkly Rep 2018; 67:931.</a></li><li><a class="nounderline abstract_t">Laws RL, Jain S, Cooksey GS, et al. Coccidioidomycosis outbreak among inmate wildland firefighters: California, 2017. Am J Ind Med 2021; 64:266.</a></li><li><a class="nounderline abstract_t">Dodge RR, Lebowitz MD, Barbee R, Burrows B. Estimates of C. immitis infection by skin test reactivity in an endemic community. Am J Public Health 1985; 75:863.</a></li><li><a class="nounderline abstract_t">Tsang CA, Anderson SM, Imholte SB, et al. Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007-2008. Emerg Infect Dis 2010; 16:1738.</a></li><li><a class="nounderline abstract_t">Park BJ, Sigel K, Vaz V, et al. An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. J Infect Dis 2005; 191:1981.</a></li><li><a class="nounderline abstract_t">Mertz LE, Blair JE. Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. Ann N Y Acad Sci 2007; 1111:343.</a></li><li><a class="nounderline abstract_t">Forseth J, Rohwedder JJ, Levine BE, Saubolle MA. Experience with needle biopsy for coccidioidal lung nodules. Arch Intern Med 1986; 146:319.</a></li><li><a class="nounderline abstract_t">Hernández JL, Echevarría S, García-Valtuille A, et al. Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis 1997; 16:592.</a></li><li><a class="nounderline abstract_t">Deresinski SC, Stevens DA. Coccidioidomycosis in compromised hosts. Experience at Stanford University Hospital. Medicine (Baltimore) 1975; 54:377.</a></li><li><a class="nounderline abstract_t">Ampel NM. Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area. Med Mycol 1999; 37:245.</a></li><li><a class="nounderline abstract_t">Gade L, McCotter OZ, Bowers JR, et al. The detection of Coccidioides from ambient air in Phoenix, Arizona: Evidence of uneven distribution and seasonality. Med Mycol 2020; 58:552.</a></li><li><a class="nounderline abstract_t">Sun SH, Cole GT, Drutz DJ, Harrison JL. Electron-microscopic observations of the Coccidioides immitis parasitic cycle in vivo. J Med Vet Mycol 1986; 24:183.</a></li><li class="breakAll">Cole GT, Sun SH. Arthroconidium - spherule - endospore transformation in Coccidioides immitis. In: Fungal Dimorphism, Szaniszlo PJ (Ed), Plenum Publishing Corporation, New York City 1985. p.281.</li><li><a class="nounderline abstract_t">Stevens DA, Clemons KV, Levine HB, et al. Expert opinion: what to do when there is Coccidioides exposure in a laboratory. Clin Infect Dis 2009; 49:919.</a></li><li><a class="nounderline abstract_t">Johnson R, Kernerman SM, Sawtelle BG, et al. A reformulated spherule-derived coccidioidin (Spherusol) to detect delayed-type hypersensitivity in coccidioidomycosis. Mycopathologia 2012; 174:353.</a></li><li><a class="nounderline abstract_t">Nesbit LA, Knox KS, Nguyen CT, et al. Immunological characterization of bronchoalveolar lavage fluid in patients with acute pulmonary coccidioidomycosis. J Infect Dis 2013; 208:857.</a></li><li><a class="nounderline abstract_t">Li L, Dial SM, Schmelz M, et al. Cellular immune suppressor activity resides in lymphocyte cell clusters adjacent to granulomata in human coccidioidomycosis. Infect Immun 2005; 73:3923.</a></li><li><a class="nounderline abstract_t">Graham AR, Sobonya RE, Bronnimann DA, Galgiani JN. Quantitative pathology of coccidioidomycosis in acquired immunodeficiency syndrome. Hum Pathol 1988; 19:800.</a></li><li><a class="nounderline abstract_t">SMITH CE, BEARD RR. Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am J Public Health Nations Health 1946; 36:1394.</a></li><li><a class="nounderline abstract_t">Smith CE. Epidemiology of Acute Coccidioidomycosis with Erythema Nodosum ("San Joaquin" or "Valley Fever"). Am J Public Health Nations Health 1940; 30:600.</a></li><li><a class="nounderline abstract_t">Crum N, Lamb C, Utz G, et al. Coccidioidomycosis outbreak among United States Navy SEALs training in a Coccidioides immitis-endemic area--Coalinga, California. J Infect Dis 2002; 186:865.</a></li><li><a class="nounderline abstract_t">Perera P, Stone S. Coccidioidomycosis in workers at an archeologic site-Dinosaur National Monument, Utah, June-July 2001. Ann Emerg Med 2002; 39:566.</a></li><li><a class="nounderline abstract_t">Bronnimann DA, Adam RD, Galgiani JN, et al. Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med 1987; 106:372.</a></li><li><a class="nounderline abstract_t">Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990; 69:384.</a></li><li><a class="nounderline abstract_t">Singh VR, Smith DK, Lawerence J, et al. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis 1996; 23:563.</a></li><li class="breakAll">Lundergan LL, Kerrick SS, Galgiani JN. Coccidioidomycosis at a university outpatient clinic: A clinical description. In: Coccidioidomycosis, Einstein HE, Catanzaro A (Eds), Proceedings of the Fourth International Conference. Washington: National Foundation for Infectious Diseases; 1985:47.</li><li><a class="nounderline abstract_t">Goldstein DM, Louie S. Primary pulmonary coccidioidomycosis; report of an epidemic of 75 cases. War Med 1943; 4:299.</a></li><li><a class="nounderline abstract_t">Colburn JR. Roentgenological types of pulmonary lesions in primary coccidioidomycosis. Am J Roentgenol 1944; 51:1.</a></li><li><a class="nounderline abstract_t">Willett FM, Weiss A. Coccidioidomycosis in Southern California; report of a new endemic area with a review of 100 cases. Ann Intern Med 1945; 23:349.</a></li><li><a class="nounderline abstract_t">SWEIGERT CF, TURNER JW, GILLESPIE JB. Clinical and roentgenologic aspects of coccidioidomycosis. Am J Med Sci 1946; 212:652.</a></li><li><a class="nounderline abstract_t">TAYLOR AB, BRINEY AK. Observations on primary coccidioidomycosis. Ann Intern Med 1949; 30:1224.</a></li><li><a class="nounderline abstract_t">Crum NF, Lederman ER, Stafford CM, et al. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 2004; 83:149.</a></li><li><a class="nounderline abstract_t">Valdivia L, Nix D, Wright M, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis 2006; 12:958.</a></li><li><a class="nounderline abstract_t">Kim MM, Blair JE, Carey EJ, et al. Coccidioidal pneumonia, Phoenix, Arizona, USA, 2000-2004. Emerg Infect Dis 2009; 15:397.</a></li><li><a class="nounderline abstract_t">Ampel NM, Ryan KJ, Carry PJ, et al. Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature. Medicine (Baltimore) 1986; 65:312.</a></li><li><a class="nounderline abstract_t">DiCaudo DJ, Ortiz KJ, Mengden SJ, Lim KK. Sweet syndrome (acute febrile neutrophilic dermatosis) associated with pulmonary coccidioidomycosis. Arch Dermatol 2005; 141:881.</a></li><li><a class="nounderline abstract_t">Yozwiak ML, Lundergan LL, Kerrick SS, Galgiani JN. Symptoms and routine laboratory abnormalities associated with coccidioidomycosis. West J Med 1988; 149:419.</a></li><li><a class="nounderline abstract_t">Fierer J, Burton DW, Haghighi P, Deftos LJ. Hypercalcemia in disseminated coccidioidomycosis: expression of parathyroid hormone-related peptide is characteristic of granulomatous inflammation. Clin Infect Dis 2012; 55:e61.</a></li><li><a class="nounderline abstract_t">Sakata KK, Grys TE, Chang YH, et al. Serum procalcitonin levels in patients with primary pulmonary coccidioidomycosis. Ann Am Thorac Soc 2014; 11:1239.</a></li><li><a class="nounderline abstract_t">Donovan FM, Ramadan FA, Khan SA, et al. Comparison of a Novel Rapid Lateral Flow Assay to Enzyme Immunoassay Results for Early Diagnosis of Coccidioidomycosis. Clin Infect Dis 2021; 73:e2746.</a></li><li><a class="nounderline abstract_t">Zangeneh TT, Malo J, Luraschi-Monjagatta C, et al. Positive (1-3) B-d-glucan and cross reactivity of fungal assays in coccidioidomycosis. Med Mycol 2015; 53:171.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Bays DJ, Johnson SM, et al. Serum (1-&gt;3)-β-D-glucan measurement in coccidioidomycosis. J Clin Microbiol 2012; 50:3060.</a></li><li><a class="nounderline abstract_t">Merchant M, Romero AO, Libke RD, Joseph J. Pleural effusion in hospitalized patients with Coccidioidomycosis. Respir Med 2008; 102:537.</a></li><li><a class="nounderline abstract_t">SMITH CE, BEARD RR, SAITO MT. Pathogenesis of coccidioidomycosis with special reference to pulmonary cavitation. Ann Intern Med 1948; 29:623.</a></li><li><a class="nounderline abstract_t">Crum-Cianflone NF, Truett AA, Teneza-Mora N, et al. Unusual presentations of coccidioidomycosis: a case series and review of the literature. Medicine (Baltimore) 2006; 85:263.</a></li><li><a class="nounderline abstract_t">Cairns L, Blythe D, Kao A, et al. Outbreak of coccidioidomycosis in Washington state residents returning from Mexico. Clin Infect Dis 2000; 30:61.</a></li><li><a class="nounderline abstract_t">Desai SA, Minai OA, Gordon SM, et al. Coccidioidomycosis in non-endemic areas: a case series. Respir Med 2001; 95:305.</a></li><li><a class="nounderline abstract_t">From the Centers for Disease Control. Coccidiodomycosis in travelers returning for Mexico--Pennsylvania, 2000. JAMA 2000; 284:2990.</a></li><li><a class="nounderline abstract_t">Chaturvedi V, Ramani R, Gromadzki S, et al. Coccidioidomycosis in New York State. Emerg Infect Dis 2000; 6:25.</a></li><li><a class="nounderline abstract_t">Toda M, Gonzalez FJ, Fonseca-Ford M, et al. Notes from the Field: Multistate Coccidioidomycosis Outbreak in U.S. Residents Returning from Community Service Trips to Baja California, Mexico - July-August 2018. MMWR Morb Mortal Wkly Rep 2019; 68:332.</a></li><li><a class="nounderline abstract_t">Galgiani JN. Coccidioidomycosis: changing perceptions and creating opportunities for its control. Ann N Y Acad Sci 2007; 1111:1.</a></li><li><a class="nounderline abstract_t">Campion JM, Gardner M, Galgiani JN . Coccidioidomycosis (valley Fever) in older adults: An increasing problem. Arizona Geriatr Soc J 2003; 8:3.</a></li><li><a class="nounderline abstract_t">Chang DC, Anderson S, Wannemuehler K, et al. Testing for coccidioidomycosis among patients with community-acquired pneumonia. Emerg Infect Dis 2008; 14:1053.</a></li><li><a class="nounderline abstract_t">Smith DJ, Free RJ, Thompson Iii GR, et al. Clinical Testing Guidance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis in Patients with Community-Acquired Pneumonia for Primary and Urgent Care Providers. Clin Infect Dis 2023.</a></li><li><a class="nounderline abstract_t">DiTomasso JP, Ampel NM, Sobonya RE, Bloom JW. Bronchoscopic diagnosis of pulmonary coccidioidomycosis. Comparison of cytology, culture, and transbronchial biopsy. Diagn Microbiol Infect Dis 1994; 18:83.</a></li><li><a class="nounderline abstract_t">Binnicker MJ, Buckwalter SP, Eisberner JJ, et al. Detection of Coccidioides species in clinical specimens by real-time PCR. J Clin Microbiol 2007; 45:173.</a></li><li><a class="nounderline abstract_t">Hall KA, Sethi GK, Rosado LJ, et al. Coccidioidomycosis and heart transplantation. J Heart Lung Transplant 1993; 12:525.</a></li><li><a class="nounderline abstract_t">Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982; 142:489.</a></li><li><a class="nounderline abstract_t">Holt CD, Winston DJ, Kubak B, et al. Coccidioidomycosis in liver transplant patients. Clin Infect Dis 1997; 24:216.</a></li><li><a class="nounderline abstract_t">Rutala PJ, Smith JW. Coccidioidomycosis in potentially compromised hosts: the effect of immunosuppressive therapy in dissemination. Am J Med Sci 1978; 275:283.</a></li><li><a class="nounderline abstract_t">Pappagianis D, Lindsay S, Beall S, Williams P. Ethnic background and the clinical course of coccidioidomycosis. Am Rev Respir Dis 1979; 120:959.</a></li><li><a class="nounderline abstract_t">Crum NF, Lederman ER, Hale BR, et al. A cluster of disseminated coccidioidomycosis cases at a US military hospital. Mil Med 2003; 168:460.</a></li><li><a class="nounderline abstract_t">Santelli AC, Blair JE, Roust LR. Coccidioidomycosis in patients with diabetes mellitus. Am J Med 2006; 119:964.</a></li><li class="breakAll">Johnson RH, Caldwell JW, Welch G, et al. The great coccidioidomycosis epidemic: Clinical features. In: Coccidioidomycosis. Proceedings of the 5th International Conference, H. E. Einstein HE, Catanzaro A (Eds), National Foundation for Infectious Diseases, Washington 1996, p.77.</li><li><a class="nounderline abstract_t">Blair JE, Mayer AP, Currier J, et al. Coccidioidomycosis in elderly persons. Clin Infect Dis 2008; 47:1513.</a></li><li><a class="nounderline abstract_t">Blair JE, Ampel NM, Hoover SE. Coccidioidomycosis in selected immunosuppressed hosts. Med Mycol 2019; 57:S56.</a></li><li><a class="nounderline abstract_t">Ampel NM, Giblin A, Mourani JP, Galgiani JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis 2009; 48:172.</a></li><li><a class="nounderline abstract_t">Blair JE, Chang YH, Cheng MR, et al. Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis. Emerg Infect Dis 2014; 20:983.</a></li><li><a class="nounderline abstract_t">Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000; 133:676.</a></li><li><a class="nounderline abstract_t">Brewer AC, Huber JT, Girardo ME, et al. Cutaneous effects associated with fluconazole in patients treated for coccidioidomycosis. Int J Dermatol 2019; 58:250.</a></li><li><a class="nounderline abstract_t">Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53:1060.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Lewis JS 2nd, Nix DE, Patterson TF. Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis. Med Mycol 2019; 57:S76.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis 2016; 63:356.</a></li><li><a class="nounderline abstract_t">Fitterer C, Berg Z, Halfdanarson TR, et al. Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature. Mycopathologia 2016; 181:787.</a></li><li><a class="nounderline abstract_t">Blair JE, Smilack JD, Caples SM. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005; 165:113.</a></li><li><a class="nounderline abstract_t">Zahid U, Shaukat AA, Hassan N, Anwer F. Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma. Immunotherapy 2017; 9:1061.</a></li><li><a class="nounderline abstract_t">Vinh DC, Masannat F, Dzioba RB, et al. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin Infect Dis 2009; 49:e62.</a></li><li><a class="nounderline abstract_t">Sampaio EP, Hsu AP, Pechacek J, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 2013; 131:1624.</a></li><li><a class="nounderline abstract_t">Powers AE, Bender JM, Kumánovics A, et al. Coccidioides immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in signal transducer and activator of transcription. Pediatr Infect Dis J 2009; 28:664.</a></li><li><a class="nounderline abstract_t">McHardy IH, Dinh BN, Waldman S, et al. Coccidioidomycosis Complement Fixation Titer Trends in the Age of Antifungals. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev 1990; 3:247.</a></li><li><a class="nounderline abstract_t">Muir Bowers J, Mourani JP, Ampel NM. Fatigue in coccidioidomycosis. Quantification and correlation with clinical, immunological, and nutritional factors. Med Mycol 2006; 44:585.</a></li></ol></div><div id="topicVersionRevision">Topic 2460 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108067" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21156479" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672423" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Novel approach to designing primers for identification and distinction of the human pathogenic fungi Coccidioides immitis and Coccidioides posadasii by PCR amplification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470238" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470238" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470238" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23535687" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increase in reported coccidioidomycosis--United States, 1998-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223598" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Coccidioidomycosis acquired in Washington State.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24848217" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Coccidioides immitis identified in soil outside of its known range - Washington, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25165087" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Valley fever: finding new places for an old disease: Coccidioides immitis found in Washington State soil associated with recent human infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11724157" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Coccidioidomycosis in workers at an archeologic site--Dinosaur National Monument, Utah, June-July 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5059262" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An epidemic of coccidioidomycosis among archeology students in northern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5059262" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An epidemic of coccidioidomycosis among archeology students in northern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5059262" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An epidemic of coccidioidomycosis among archeology students in northern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21695034" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The public health impact of coccidioidomycosis in Arizona and California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332089" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Coccidioidomycosis in California state correctional institutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053941" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A point-source outbreak of Coccidioidomycosis among a highway construction crew.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30138303" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Coccidioidomycosis Outbreak Among Workers Constructing a Solar Power Farm - Monterey County, California, 2016-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33484179" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Coccidioidomycosis outbreak among inmate wildland firefighters: California, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4025646" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Estimates of C. immitis infection by skin test reactivity in an endemic community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21029532" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871133" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363440" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Coccidioidomycosis in rheumatology patients: incidence and potential risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3947192" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Experience with needle biopsy for coccidioidal lung nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9323471" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1099399" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Coccidioidomycosis in compromised hosts. Experience at Stanford University Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421859" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31506673" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The detection of Coccidioides from ambient air in Phoenix, Arizona: Evidence of uneven distribution and seasonality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3735028" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Electron-microscopic observations of the Coccidioides immitis parasitic cycle in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3735028" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Electron-microscopic observations of the Coccidioides immitis parasitic cycle in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663562" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Expert opinion: what to do when there is Coccidioides exposure in a laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22669545" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A reformulated spherule-derived coccidioidin (Spherusol) to detect delayed-type hypersensitivity in coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23737603" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Immunological characterization of bronchoalveolar lavage fluid in patients with acute pulmonary coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972478" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cellular immune suppressor activity resides in lymphocyte cell clusters adjacent to granulomata in human coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3402972" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Quantitative pathology of coccidioidomycosis in acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20278046" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18015234" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Epidemiology of Acute Coccidioidomycosis with Erythema Nodosum ("San Joaquin" or "Valley Fever").</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12198626" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Coccidioidomycosis outbreak among United States Navy SEALs training in a Coccidioides immitis-endemic area--Coalinga, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11973568" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Coccidioidomycosis in workers at an archeologic site-Dinosaur National Monument, Utah, June-July 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3813236" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Coccidioidomycosis in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2146461" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879781" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879781" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Primary pulmonary coccidioidomycosis; report of an epidemic of 75 cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Roentgenological types of pulmonary lesions in primary coccidioidomycosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Coccidioidomycosis in Southern California; report of a new endemic area with a review of 100 cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20278434" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical and roentgenologic aspects of coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18150185" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Observations on primary coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15118543" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707052" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Coccidioidomycosis as a common cause of community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19239751" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Coccidioidal pneumonia, Phoenix, Arizona, USA, 2000-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3528738" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027305" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sweet syndrome (acute febrile neutrophilic dermatosis) associated with pulmonary coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3227686" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Symptoms and routine laboratory abnormalities associated with coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22670039" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hypercalcemia in disseminated coccidioidomycosis: expression of parathyroid hormone-related peptide is characteristic of granulomatous inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25168059" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Serum procalcitonin levels in patients with primary pulmonary coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818956" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of a Novel Rapid Lateral Flow Assay to Enzyme Immunoassay Results for Early Diagnosis of Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25541557" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Positive (1-3) B-d-glucan and cross reactivity of fungal assays in coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22692738" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Serum (1-&gt;3)-β-D-glucan measurement in coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164951" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pleural effusion in hospitalized patients with Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18890266" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pathogenesis of coccidioidomycosis with special reference to pulmonary cavitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16974211" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Unusual presentations of coccidioidomycosis: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619734" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Outbreak of coccidioidomycosis in Washington state residents returning from Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316114" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Coccidioidomycosis in non-endemic areas: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11188066" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : From the Centers for Disease Control. Coccidiodomycosis in travelers returning for Mexico--Pennsylvania, 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653565" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Coccidioidomycosis in New York State.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30973851" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Notes from the Field: Multistate Coccidioidomycosis Outbreak in U.S. Residents Returning from Community Service Trips to Baja California, Mexico - July-August 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17344530" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Coccidioidomycosis: changing perceptions and creating opportunities for its control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Coccidioidomycosis (valley Fever) in older adults: An increasing problem</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18598625" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Testing for coccidioidomycosis among patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37802909" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical Testing Guidance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis in Patients with Community-Acquired Pneumonia for Primary and Urgent Care Providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8062536" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bronchoscopic diagnosis of pulmonary coccidioidomycosis. Comparison of cytology, culture, and transbronchial biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108077" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Detection of Coccidioides species in clinical specimens by real-time PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329432" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Coccidioidomycosis and heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7039544" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Coccidioidomycosis in renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114150" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Coccidioidomycosis in liver transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/686038" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Coccidioidomycosis in potentially compromised hosts: the effect of immunosuppressive therapy in dissemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/507518" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ethnic background and the clinical course of coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12834136" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A cluster of disseminated coccidioidomycosis cases at a US military hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071165" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Coccidioidomycosis in patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071165" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Coccidioidomycosis in patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990061" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Coccidioidomycosis in elderly persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29669037" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Coccidioidomycosis in selected immunosuppressed hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19072555" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24865953" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074900" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30229876" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cutaneous effects associated with fluconazole in patients treated for coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045955" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Treatment of refractory coccidioidomycosis with voriconazole or posaconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30690601" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169478" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27492230" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642886" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Coccidioidomycosis in patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032736" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681704" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23541320" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483664" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Coccidioides immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in signal transducer and activator of transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30257902" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Coccidioidomycosis Complement Fixation Titer Trends in the Age of Antifungals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2200605" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Serology of coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17071551" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Fatigue in coccidioidomycosis. Quantification and correlation with clinical, immunological, and nutritional factors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
